Rosen Law Firm Urges Immutep Investors to Join Class Action Lawsuit for Securities Claims

Rosen Law Firm's Investigation of Immutep Ltd.

The global investor rights advocate, Rosen Law Firm, is launching an investigation into potential securities claims linked to investors of Immutep Ltd. (NASDAQ: IMMP). The investigation arises from unsettling allegations that Immutep may have misrepresented vital business information to its shareholders, leading to significant financial losses. This news has understandably raised concerns among investors, prompting a call for increased scrutiny into the company's practices.

On March 13, 2026, Immutep disclosed through a press release that the Independent Data Monitoring Committee (IDMC) had recommended the discontinuation of the TACTI-004 Phase III study evaluating the efficacy of eftilagimod alfa, an investigational treatment for non-small cell lung cancer. The recommendation stemmed from a planned interim analysis that deemed the trial ineffective based on available safety and efficacy data. Following this announcement, there was a dramatic decline in the stock price of Immutep's American Depositary Receipts (ADRs), which plummeted by 82.6%, closing at $0.48 per ADR on the same day. This sharp drop highlighted the potential implications of the misleading information that may have been provided to investors prior to this announcement.

Rosen Law Firm is encouraging all investors who acquired Immutep securities to explore their options for recovery. The law firm operates on a contingency fee basis, meaning that investors can join this class action lawsuit without incurring upfront costs. This approach makes it accessible for affected shareholders to seek compensation without the burden of immediate financial outlay. Interested parties can easily join the forthcoming class action suit by submitting their information through the designated link on Rosen Legal's website or by reaching out directly to attorney Phillip Kim for guidance.

Investors are urged to be judicious when selecting legal representation in matters of this nature. The Rosen Law Firm is distinguished by its extensive experience in handling securities class action litigation, underscored by its noteworthy achievements, including securing one of the largest settlements in a case against a Chinese company. The firm's concentration on shareholder derivative litigation and securities class actions, coupled with its accolades—such as being recognized by ISS Securities Class Action Services for several consecutive years—establishes its credibility in advocating for investor rights.

This investigation is crucial in shedding light on the practices of Immutep and ensuring accountability. Rosen Law Firm firmly believes that no investor should suffer losses due to misinformation from publicly traded companies.

Potential class action participants can find more updates on the situation by following the Rosen Law Firm on their social media channels and visiting their website for ongoing developments. The firm remains dedicated to recuperating losses for investors and upholding the integrity of financial markets. Interested parties should act promptly to secure their interests and align themselves with a firm well-equipped to navigate the complexities of securities law.

Investors are encouraged to visit Rosen Law Firm's website or contact the firm directly via phone or email for more detailed information regarding their rights and the next steps in this evolving situation.

End of Article